Posted by Michael Wonder on 23 Aug 2018
FDA adds four tropical diseases to priority review voucher program to encourage drug development in areas of unmet need
23 August 2018 - Today, the U.S. FDA announced the addition of Lassa fever, chikungunya virus disease, rabies and cryptococcal meningitis to the list of tropical diseases.
Applicants who submit applications for drug or biological products to prevent or treat these diseases may qualify for a tropical disease priority review voucher (PRV).
A tropical disease PRV can be used to obtain priority review of a subsequent drug application that does not itself qualify for priority review.
